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T cell activation is a key event in the adaptive immune
system and vital in the generation of protective cellular
and humoral immunity. Activation is required to
generate CD4 effector T cell responses and provide
help for B cell and cytotoxic T cell responses. While
defective T responses to foreign antigen result in
infectious pathology, over-reactive T cell responses
against self-antigens result in autoimmunity and, in a
transplantation setting, tissue rejection. Understand-
ing howTcell activation is normally regulated is critical
to therapeutic intervention and the CD28/CTLA-4
(CD152) pathway represents the initial activation
checkpoint in molecular terms. In particular, while
the CTLA-4 pathway is well established as an essential
regulator of self-reactivity, its mechanism of action is
still uncertain. Such mechanistic issues are important
given its central position in T cell activation and the
increasing number of therapeutic modalities aimed at
manipulating the CD28/CTLA-4 pathway. Here, we
provide an updated view of CTLA-4 biology, reviewing
the established features of the systemand highlighting
its interplay with CD28. We then discuss how recent
progress in our understanding of this pathway affects
our interpretations following intervention.
Abbreviations: dABs, domain antibodies; Tregs, regu-
latory T cells
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A Functional Overview of the CD28/CTLA-4
Pathway
CD28 is expressed on the surface of the majority of na€ıve
CD4 and CD8 T cells and is themajor costimulatorymolecule
in initial T cell activation. Together with engagement of the T
cell receptor CD28 ligation results in the augmentation of
many aspects of T cell–mediated immunity (1–3). Conse-
quently, mice deficient in CD28 show an array of immune
defects including impaired Tcell activation, a lack of T cell help
for B cells and poor memory T cell responses, all highlighting
the importance of CD28 costimulation in the generation of
effective T cell responses and immune memory.
The immune stimulatory features of the CD28 pathway are
triggered by engagement of two well-described ligands
found on antigen-presenting cells (4). The two ligands CD80
(B7/BB1 or B7-1) and CD86 (B7-2) were, until recently,
thought to be the sole ligands for CD28 and CTLA-4;
however, there are recent reports that human (but not
mouse) CD28 and CTLA-4, can also bind to the ICOS
ligand (5). In addition, the PD-1 ligand, PD-L1 can also
interact with CD80 (6). The significance of these novel
interactions is still emerging and will not be discussed
further here. Importantly, the expression of CD80 andCD86
is up-regulated in response to inflammatory stimuli includ-
ing Toll-like receptor stimulation. As such, up-regulation of
ligands is seen as a key link between innate ‘‘danger’’
signals and the triggering of an effective adaptive immune
response (7). Despite structural and affinity differences (8)
which would suggest functional differences, to date, the
current view is that CD80 and CD86 have largely redundant
or overlapping functions as represented in Figure 1 (9,10).
In addition to binding to CD28, both CD80 and CD86 also
bind to the inhibitory protein CTLA-4, which is a CD28
homologue, expressed on activated T cells and especially
regulatory T cells (Tregs) (11). From a functional perspec-
tive, the most striking observation is that in contrast to
CD28, where deficiency leads to lack of effective T cell
responses, CTLA-4-deficient mice suffer from a fatal
overactivated phenotype resulting in profound autoimmu-
nity driven by self-reactive T cells (12,13). This functional
dichotomy between CD28 and CTLA-4 is even more
striking given that these two diametrically opposite out-
comes are controlled by interactionswith the same ligands.
The CD28/CTLA-4 pathway is therefore perhaps best
viewed as an integrated system,which controls the balance
between T cell activation and self-tolerance, in a process
that is influenced by the expression of two shared ligands.
Fundamental Concepts
At present, there are a large number of interpretations of
how the CTLA-4 pathway functions based on a wide range
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of experiments. We will not try to cover all experimental
observations, but concentrate on selected ideas in order to
generate a conceptual framework for understanding how
the various manipulations of the CD28/CTLA-4 pathway
available clinically might impact immune function.
CTLA-4 as an inhibitory signal?
Based predominantly on studies using agonistic anti-CTLA-4
antibodies, ideas relating toCTLA-4 function have frequently
focused on the concept of an inhibitory signal preventing
T cell activation (14,15). According to this concept, ligand
binding to CTLA-4 (up-regulated on activated T cells) would
be expected to generate intrinsic inhibitory signals that
‘‘switch off’’ T cell activation, proliferation and IL-2
production. This has been expanded to include roles for
the direct recruitment of phosphatases (16), effects on T cell
adhesion and motility (17) and proposed roles for various
splice variants of CTLA-4 (18–20) with presumed inhibitory
signaling capacity. The concept that emerges from these
studies is that CTLA-4 possesses an inhibitory signaling
capacity. However, there are still questions over the extent
to which cross-linked antibodies to CTLA-4 are a faithful
mimic of CTLA-4 engagement by its ligands and the nature
of inhibitory signals still remains uncertain. Therefore, while
numerous cell-intrinsic concepts for CTLA-4 function have
been proposed and discussed (21–24) the role of such
signals in CTLA-4 function in vivo remains unestablished.
A cell extrinsic function for CTLA-4 in vivo
A major challenge to the physiological importance of the
cell-intrinsic signaling mechanisms mentioned above is a
series of straightforward and widely repeated experiments
in chimericmice that possess both CTLA-4WT andCTLA-4-
deficient T cells. This reveals that mice containing mixtures
of CTLA-4/ and CTLA-4þ/þ T cells fail to develop lethal
lymphoproliferative disease and the CTLA-4/ T cells
maintain a normal nonactivated phenotype (25–27). It
follows that the critical CTLA-4 functions, required to
prevent systemic autoimmunity, are therefore T cell-
extrinsic. Such data fit well with the possibility of CTLA-4
acting in a suppressive manner, such as an effector
molecule on Tregs, but are much less compatible with
direct inhibitory signaling in effector T cells. In support of
the concept of extrinsic regulation it has become increas-
ingly evident that CTLA-4 is indeed an important compo-
nent of Treg function. This issue has been convincingly
demonstrated by recent experiments using Tregs from
CTLA-4-deficient mice (28) or conditionally deficient
Tregs (29), which reveal CTLA-4 to be critical for Treg
function in the prevention of autoimmunity. Further
evidence for the importance of CTLA-4 to Tregs has
recently come from the demonstration that expression of
CTLA-4 and repression of IL-2 expression are two essential
components to confer a Treg phenotype (30).
CD28 and CTLA-4 functions are tightly connected
The sharing of ligands between CD28 and CTLA-4 high-
lights the key principle that CD28 and CTLA-4 functions are
closely intertwined. Importantly, it is evident that the fatal
phenotype caused by CTLA-4 deficiency occurs as a result
of CD28-dependent and ligand-driven T cell activation.
Accordingly, CTLA-4-deficient mice lacking both ligands,
those with CD28 deficiency or those treated with ligand
blocking compounds (e.g. CTLA-4-Ig) all have substantially
ameliorated disease (31,32). Thus, the concept that
emerges is that a key role of CTLA-4 is to directly control
stimulation of the CD28 pathway via its natural ligands.
Transendocytosis as a mechanism for CTLA-4
function
Interestingly, the principle of using CTLA-4 to inhibit CD28
function by preventing access to ligands underpins the
development of both abatacept and belatacept, yet has
traditionally not been widely thought of as a mechanism
for CTLA-4 function physiologically. However, we recently
identified a novelmolecularmechanismof CTLA-4 function,
which exploits exactly this principle. Based initially on
observations using cell coculture models we observed that
robust transfer of ligands (CD80 and CD86) could occur
between ligand-expressing donor cells in contact with
CTLA-4 expressing recipient cells (33). This observation
prompted the idea that CTLA-4 could potentially act as a
physical ligand-capturing device thereby depleting shared
CD28-ligands from antigen-presenting cells. Subsequent
experiments revealed that the entire ligand (either CD80 or
CD86) including its cytoplasmic domain could be trans-
ferred to the CTLA-4 recipient cell and that internalized
ligands were subsequently degraded consistent with the
Figure 1: Shared interactions between CD28 and CTLA-4
family members. Two main ligands, CD80 and CD86 (drawn
generically here for clarity), are present on activated antigen-
presenting cells (APC) and can bind to both CD28 and CTLA-4.
Ligand binding toCD28provides costimulatory signals in addition to
TCR stimulation whereas CTLA-4 acts to inhibit ligand-driven CD28
function. Additional interactions between CD80 and the PD-1
ligand PD-L1 and interactions between the ICOS ligand and human
CD28/CTLA-4 have also been proposed. The sharing of ligands
between activatory and inhibitory receptors means the pathway is
an integrated system and as such perturbations in one interaction
can influence others in the pathway.
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known pattern of CTLA-4 intracellular trafficking (34). This
process occurs in vivo and is seen only in CD4þ CD25þ T
cells (including, but not restricted to Tregs) and removal of
ligands by transendocytosis can therefore be considered as
a cell-extrinsic form of ligand blockade. This process is
reminiscent of the mechanism used by abatacept or
belatacept, with the difference being that with trans-
endocytosis ligand is physically removed as opposed to
being simply blocked.
Consistent with the concept of transendocytosis, consid-
erable evidence indicates that CTLA-4 is able to alter the
levels of CD80 and CD86 on antigen-presenting
cells (29,35–37). Transendocytosis by CTLA-4 therefore
provides a plausable explanation for how this can be
achieved as well as a cogent reason why CD28 and CTLA-4
share ligands: If this were not the case then CTLA-4 would
be unable to control CD28 stimulation in this model. In
terms of functional significance, the reduction in the level of
costimulation available through CD28 may be sufficient to
suppress activation of weakly self-reactive T cells that
emerge from the thymus and thus CTLA-4 expression can
regulate autoimmunity. Taken together transendocytosis
provides an alternative and simple model of antigen-
specific, T cell–extrinsic suppression compatible with a
function for CTLA-4 on Tregs and which encompasses
many of the known features of CTLA-4 biology.
Manipulation of the CD28/CTLA-4 pathway
The above discussion highlights the fact that CD28
engagement represents a key checkpoint in the activation
of T cells and that CTLA-4may directly oppose this function.
Therefore, rather than viewing CD28 and CTLA-4 as
receptors that function separately, the pathway is best
viewed as an integrated (and finely balanced) system with
CTLA-4 providing a counter balance to CD28 function.
Perturbation of this balance can therefore have a number of
potential consequences depending on the functional
mechanisms that are considered to be at play. Below we
consider several different manipulation approaches and
how they may potentially affect immune function in both
obvious and less obvious ways.
Ligand Blockade
Ligand blockade has to date been themostwidely exploited
approach for manipulation of the CD28/CTLA-4 pathway.
Blocking antibodies to CD80 and CD86 have been
developed as a strategy for blocking the CD28/CTLA-4
pathway; however, despite some potential advantages for
tailoring immune responses, selective ligand blockade has
not been widely applied in a clinical setting.
In contrast to selective blockade of CD80 and CD86,
simultaneous blockade of both ligands has been widely
exploited in the context of the fusion protein CTLA-4-Ig now
available clinically in two forms: abatacept and belatacept
(Figure 2A and B). By exploiting the higher affinity of CTLA-4
for its ligands, these compounds have been shown to
inhibit T cell responses in models of autoimmune disease
and in transplantation models (38,39).
The humanized version of CTLA-4-Ig, which incorporates a
modified IgG Fc domain (abatacept), has been approved for
the treatment of moderate to severe rheumatoid arthritis in
patients who have not responded to other disease-
modifying drugs (40). However, due to the limited efficacy
of abatacept in nonhuman primate models of transplanta-
tion, attention has now turned to an artificially engineered
higher-affinity CTLA-4-Ig variant, LEA29Y (belatacept). This
sequence modification translates into elevated affinity for
both CD86 and CD80with an associated increased potency
of CD28 inhibition (41,42). Belatacept also has an altered
bias in that it has a greater relative increase in CD86 binding
compared to CD80. Belatacept has now been approved for
clinical use in immunosuppression regimens following renal
transplantation (43,44).
While blocking CD28 ligands with abatacept and belatacept
is simple in concept, there are a number of theoretical
considerations affecting the use of these compounds.
Rather obviously, the first is that such approaches can
realistically only hope to inhibit responses that are in fact
CD28 dependent. What makes a T cell response CD28
dependent is not entirely clear but is generally thought to
involve the intensity of TCR engagement, such that strong
TCR stimuli may require less CD28 costimulation (45). A
second issue is that memory T cells may have lower
requirements for CD28 and may therefore be more difficult
to control via costimulation blockade. Together these
caveats may relate to the difficulty in translating effective
blockade in animal models, which are predominantly
immunologically na€ıve into the human setting where
alloresponses may come from established memory clones
as well as na€ıve T cells.
Another consideration relating to ligand blockade is its
potential impact upon Treg biology. The generation,
function and maintenance of Tregs appear to be CD28-
dependent processes (46–48). Furthermore, the generation
of induced Tregs from na€ıve T cells may also involve CD28
signals (49), although this issue is contoversial (50). Despite
potential loss of Tregs due to ligand blockade, this is not
normally problematic since effector responses are con-
comitantly inhibited. Thus, the relative impact on Tregs
versus the degree of control over effectors may be a
significant factor in outcome. Interestingly, in one study,
in an MHC II-mismatched cardiac transplantation model,
CTLA-4-Ig promoted allograft rejection in amanner thatwas
associated with a loss of natural Tregs and changes in the
effector T cell:Treg ratio. In contrast, in a different transplant
model the dominant impact of CTLA-4-Ig was the suppres-
sion of effector T cell responseswith significantly enhanced
allograft survival (51). In line with this issue, treatment with
belatacept has been associated with higher incidences of
CTLA-4 and Costimulatory Blockade
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acute rejection (52) especially at higher doses (53), which
may be due to more effective CD28 blockade suggesting
possible effects on Tregs (Figure 2B).
Another potential issue of ligand blockade is in relation to
putative CTLA-4 inhibitory signals. If intrinsic CTLA-4
signaling is important for the control of normal effector T
cell responses, then blocking the ligands that generate such
inhibition is potentially deleterious (Figure 2B). In such a
case, exacerbated immune responses might be expected.
There appear to be examples of enhanced responses due to
both abatacept treatment (51) and belatacept treatment,
associated with an increased prevalence of acute rejec-
tion (52). However, the mechanisms underlying any
increase in responses following ligand blockade are
presently unclear. It will therefore be important to discern
if such enhanced immune responsiveness relates to an
inhibitory effect on Tregs or an intrinsic enhancement of
conventional T cell responses by removing CTLA-4 inhibi-
tion. Possible effects on Tregs include decreased levels
of IL-2 available due to effective inhibition of production
by conventional T cells or alternatively blocking intrinsic
CD28 signals required for Treg homeostasis. The fact that
problems are less apparent with abatacept compared to
belataceptmay suggest that weaker blockade by abatacept
may have some Treg sparing effect.
Anti-CD28 Specific Antibodies
Given the potential for undesirable effects of ligand
blockade strategies, CD28 blockade has been explored as
Figure 2: Possible outcomes ofmanipulating CD28/CTLA-4 pathway. Four possible manipulation strategies (A–D) are shownwith the
modifying agent highlighted in yellow. In (A) treatment with abatacept binds to both CD86 (dark blue) and CD80 (light blue). Abatacept has
the samenatural ligand binding affinities asCTLA-4 and as such has a strong preference for CD80 occupancy. This translates into incomplete
occupancy of CD86 with more complete binding to CD80. Such an approach diminishes but does not ablate CD28 signaling and may leave
sufficient CD86 available to promote regulatory T cell (Treg) survival while still attenuating CD28-dependent T cell activation. (B) Belatacept
has an engineered higher affinity for both CD80 and CD86. This results in more potent blockade of both ligands and increased capacity to
inhibit T cell responses. However, there is a possibility that such potent inhibition of CD28 could impair the homeostasis of Tregs, which are
thought to be CD28 dependent. Targeting CD28 directly can exhibit agonistic (C) or antagonistic effects (D). Agonists can promote T cell
activation but also may have the possibility to selectively expand Tregs at appropriate doses. The potential for generating unwanted T cell
stimulation is increased with this approach. (D) CD28 antagonists are the most direct approach to blocking costimulation. However, these
antibodies need to be rigorously screened for unwanted agonistic activity. High-affinity antagonists should prevent T cell activation while
leavingCTLA-4 ligands available. However, CD28blockademay also have unwantedeffects on Treg homeostasis. In all the scenarios above,
the impact on CTLA-4 function (red) is dependent on themolecular mechanism bywhich CTLA-4 is deemed towork (seemain text). The red
arrow denotes CTLA-4 function and not an inhibitory signal per se. The impact of inhibiting the above pathways on CTLA-4 function remains
the biggest uncertainty.
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an alternative in transplantation tolerance and autoimmune
treatment. However, this approach has its own challenges
since anti-CD28 antibodies can have agonistic as well as
antagonistic effects (Figure 2C and D), leading to polyclonal
T cell expansion rather than stimulation blockade. Thus for
CD28 blockade to be viable, the possibility of agonistic
activity has to be carefully considered. Importantly, anti-
bodies that display agonistic effects in vitro have often
proven antagonistic in vivo, inhibiting disease and reducing
rejection of heart, liver and skin allografts (reviewed in (54)).
Whether agonistic or antagonistic properties are evident
may therefore depend on context, for example, in the
presence of an effective ligand-driven CD28 signaling anti-
CD28 antibodies are often antagonistic, whereas in the
absence of ligands agonistic properties can be observed.
Perhaps counterintuitively, superagonistic anti-CD28 anti-
bodies that potently stimulate T cell activation (55) have
been observed to restore immune tolerance in several
autoimmune and transplantation models (56–58). This
presents something of a conundrum as to whether
enhancing Treg (superagonists) or blocking effector cells
(antagonists) is the better strategy. The former strategy of
using CD28 costimulation to expand Treg (Figure 2C) was
initially behind the ill-fated TGN1412 trial (59), suggesting it
is extremely problematic. However, recent studies have
continued to explore this approach and indicate that
selective Treg expansion is nonetheless possible with
such an approach (60).
The opposite approach to generate more efficient and
specifically antagonistic CD28 blocking drugs continues to
be explored (Figure 2D). Genetic fusion of the long-lived
serum protein a1-anti-trypsin with the single-chain-Fv
fragment from anti-CD28 (sc28AT) successfully increased
the antibody half-life and reduced proliferation of human
and primate T cells in mixed lymphocyte reactions and
inhibited cytokine production (61). More recently there has
been a report of increases in the frequency of functional
FoxP3þ and CTLA-4þ Tregs in the blood associated with
CD28 blockade (62). This finding is surprising given the
evidence that CD28 signals are generally pro-Treg genera-
tion and survival. If confirmed this suggests that a balance
can been achieved between CD28 blockade and loss of
Tregs. It will then be of interest to determine if such Tregs
are thymically derived or induced in this setting. The authors
have continued to develop further CD28 blocking reagents
and have shown one of these (FR104) prevents graft-
versus-host disease in a humanized mouse model in a
CTLA-4-dependent manner (63). Similar data were also
obtained using a CD28Fv in a cardiac allograft model (64).
Thus, it seems that while CD28 blockade affects Treg
homeostasis, their (in vitro) suppressive function can still be
maintained (62).
Other anti-CD28 fragment approaches have also been
tried using single domain antibodies (dABs) or nanobodies.
These comprise only a single VH domain and are therefore
small enough to be easily cloned in bacteria and selected for
high antigen affinity through phage or ribosome display.
Recently, the development of two dABs was reported that
were >10-fold more potent for binding to CD28 than either
sc28AT or FR104 and more effectively inhibited human
mixed lymphocyte responses (65). One attraction behind all
the CD28 antibody approaches is the potential for
preserved CTLA-4 function. For example, CD28 blockade
does not prevent downregulation of CD86 on dendritic cells
by CTLA-4þ T cells (65). However, this point may be, to
some extent, moot depending on our understanding of
CTLA-4 biology. If CTLA-4 acts by competition for, or
removal of, CD28-ligands then effective CD28 blockade
renders the continued availability of ligands largely redun-
dant. If, however, CTLA-4 acts by receiving ligand generat-
ed signals then CD28 blockade will continue to allow
additional ligand-driven inhibitory function. In this respect,
recent reports suggest that anti-CD28 dAb allowedCTLA-4-
dependent induction of the co-inhibitory protein 2B4,
whose expression on CD8þ T cells might be important
for enhancing graft survival (66). Importantly, in this study,
Liu et al (66) also showed that their anti-CD28 dAb could
substantially increase skin allograft survival. Again the
nature of the CTLA-4 involvement in this model remains to
be fully defined. The authors’ interpretation is that CD28
blockade allows the transmission of additional inhibitory
signals via CTLA-4, which are then revealed using anti-
CTLA-4 blockade. As highlighted above this concept is
not consistent with much of the basic literature on CTLA-4
in vivo (22). An alternative interpretation is that anti-CTLA-4
treatment directly affects Treg function, which works
alongside the blockade of effector responses via CD28.
Thus, while CD28 blockade would appear to be a very
fruitful strategy for immune modulation, precise details in
understanding mechanism of action are awaited.
The last two decades have witnessed very substantial
progress in manipulating the immune response via the
CD28/CTLA-4 pathway for therapeutic benefit. This prog-
ress has moved somewhat ahead of our fundamental
understanding of how the pathway operates. The mecha-
nistic gaps in our understanding, particularly relating to
CTLA-4, now need to be filled in order that precise
strategies for controlling effector T cells while preserving
natural Treg functions can be fully optimized.
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